文献速递系统性红斑狼疮其他结缔组织病

儿童期起病系统性红斑狼疮中巨噬细胞活化综合征的特征、治疗与结局

Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2018-03-02

单中心队列纳入2002至2012年就诊的403例儿童期起病系统性红斑狼疮患者,其中38例(9%)合并巨噬细胞活化综合征;68%在诊断系统性红斑狼疮同时诊断巨噬细胞活化综合征,发热是最常见表现;巨噬细胞活化综合征组死亡率5%,无巨噬细胞活化综合征组0.2%(P=0.02);多数患者经糖皮质激素治疗成功且无巨噬细胞活化综合征复发。

要点

  • 403例儿童期起病系统性红斑狼疮中38例(9%)合并巨噬细胞活化综合征,68%为同时诊断。
  • 发热是巨噬细胞活化综合征最常见临床特征,肾脏和中枢神经系统受累频率两组相似。
  • 巨噬细胞活化综合征组死亡率5%高于无巨噬细胞活化综合征组0.2%(P=0.02)。

核心结论

  • 巨噬细胞活化综合征最可能与儿童期起病系统性红斑狼疮诊断同时发生。
  • 多数巨噬细胞活化综合征患者经糖皮质激素治疗成功且无巨噬细胞活化综合征复发。
  • 尽管例数少,巨噬细胞活化综合征相比无巨噬细胞活化综合征的系统性红斑狼疮与更高的死亡风险相关。

研究设计与样本

  • 单中心队列研究,纳入2002至2012年在病童医院随访的所有儿童期起病系统性红斑狼疮患者,并识别其中诊断为巨噬细胞活化综合征者。
  • 从狼疮数据库提取人口学、临床和实验室特征、用药、住院和儿科重症监护室入住、损伤指数及死亡数据。
  • 采用Student t检验和Fisher精确检验比较连续变量和分类变量,用Poisson模型计算住院和儿科重症监护室入住的发病率比,用Kaplan-Meier生存分析检验疾病损伤累积时间。

主要发现

  • 403例儿童期起病系统性红斑狼疮患者中38例(9%)合并巨噬细胞活化综合征。
  • 68%的巨噬细胞活化综合征患者为同时诊断巨噬细胞活化综合征和系统性红斑狼疮。
  • 发热是巨噬细胞活化综合征最常见的临床特征。
  • 合并与不合并巨噬细胞活化综合征的患者在肾脏和中枢神经系统疾病频率、住院次数、平均每日激素剂量及疾病损伤时间方面相似。
  • 巨噬细胞活化综合征组死亡率为5%,无巨噬细胞活化综合征组为0.2%(P=0.02)。

关键数值与推荐

  • 403例儿童期起病系统性红斑狼疮患者中38例(9%)合并巨噬细胞活化综合征。
  • 68%的巨噬细胞活化综合征患者为同时诊断巨噬细胞活化综合征和系统性红斑狼疮。
  • 巨噬细胞活化综合征组死亡率5% vs 无巨噬细胞活化综合征组0.2%(P=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出例数少(numbers were small)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the features and treatment of macrophage activation syndrome (MAS) in a single-center cohort of patients with childhood-onset systemic lupus erythematosus (SLE), and to compare childhood-onset SLE manifestations and outcomes between those with and those without MAS. METHODS: We included all patients with childhood-onset SLE followed up at The Hospital for Sick Children from 2002 to 2012, and identified those also diagnosed as having MAS. Demographic, clinical, and laboratory features of MAS and SLE, medication use, hospital and pediatric intensive care unit (PICU) admissions, as well as damage indices and mortality data were extracted from the Lupus database. Student's t-tests and Fisher's exact tests were used to compare continuous and categorical variables, respectively. We calculated incidence rate ratios of hospital and PICU admissions comparing patients with and those without MAS, using Poisson models. Kaplan-Meier survival analysis was used to examine the time to disease damage accrual. RESULTS: Of the 403 patients with childhood-onset SLE, 38 (9%) had MAS. The majority (68%) had concomitant MAS and SLE diagnoses. Fever was the most common MAS clinical feature. The frequency of renal and central nervous system disease, hospital admissions, the average daily dose of steroids, and time to disease damage were similar between those with and those without MAS. We observed a higher mortality rate among those with MAS (5%) than those without MAS (0.2%) (P = 0.02). CONCLUSION: MAS was most likely to develop concomitantly with childhood-onset SLE diagnosis. The majority of the MAS patients were successfully treated with corticosteroids with no MAS relapses. Although the numbers were small, there was a higher risk of death associated with MAS compared to SLE without MAS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Borgia RE, Gerstein M, Levy DM, et al. Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018. PMID: 29342508. doi:10.1002/art.40417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。